CERVICAL DYSPLASIA MARKET ANALYSIS

Cervical Dysplasia Market, By Diagnosis Type (Diagnosis Test (HPV Test, Pap Smear Test, Biopsy Test) and Diagnostic Device (Colposcope)), By End User (Hospitals, Diagnostic Centers, and Ambulatory Surgery Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments:

New product launches:

In July 13, 2022, Serum Institute of India, a biotechnology company, launched a vaccine to prevent cervical cancer.
In June 16, 2022, Roche, a pharmaceutical company headquartered in Switzerland, launched a human papillomavirus (HPV) self-sampling solution in countries accepting the Conformité Européenne CE mark. This new solution enables a patient to privately collect their own sample for HPV screening.

Acquisition and partnerships:

In March 2019, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, and INOVIO, an American biotechnology company focused on the discovery, development, and commercialization of synthetic deoxyribonucleic acid (DNA) products, announced a collaboration to develop a companion diagnostic to guide clinical decision-making for the use of INOVIO’s DNA-based immunotherapy to treat cervical dysplasia caused by